The objective of the current study was to determine the prevalence and clinicopathologic characteristics of KIF5B-RET fusions (fusions of the RET and kinesin family member 5B [KIF5B] genes) in Chinese patients with NSCLC.    ///    "There was no statistically significant difference in age, sex, smoking status, pathologic stage, or histologic type between patients with and without KIF5B-RET fusions."    ///    All patients who were positive for a KIF5B-RET fusion were never-smokers.    ///    "KIF5B-RET fusions were quite rare, with a prevalence of approximately 1.5% in Chinese patients with NSCLC, and they were a little more common in patients with adenocarcinoma than in those with squamous carcinoma (1.73% vs 0.84%)."    ///    The relations between KIF5B-RET fusions and clinicopathologic characteristics were analyzed.     ///    KIF5B-RET fusions in Chinese patients with non-small cell lung cancer..     ///    "In total, 6 patients (1.5%) were identified who harbored KIF5B-RET fusions. "    ///    "Patients without KIF5B-RET fusions had a better prognosis than those with KIF5B-RET fusions (median survival, 52.6 months vs 21.0 months. "    ///    The authors screened for KIF5B-RET fusions in 392 patients with NSCLC using multiplex real-time polymerase chain reaction assay and validated all positive samples using direct sequencing.     ///    "There was no statistically significant difference in age, sex, smoking status, pathologic stage, or histologic type between patients with and without KIF5B-RET fusions. "    ///    "KIF5B-RET fusions were quite rare, with a prevalence of approximately 1.5% in Chinese patients with NSCLC, and they were a little more common in patients with adenocarcinoma than in those with squamous carcinoma (1.73% vs 0.84%). "    ///    "In addition, KIF5B-RET fusions also existed in patients with low-grade malignant neuroendocrine tumors.. "